Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Gary105 who wrote (133)	12/16/1997 5:15:00 AM
From: Ron Kline	Read Replies (1) \| Respond to of 340

Thanks for the press release Gary. Looks like Teva is doing all the right things. Controlled release generics are a great avenue for growth. One of the ways the big Pharms outsmart the generics is to develop patented controlled release products of their drug, extending the life of the expired drug patent. It looks like Teva is now going to be moving hard in the CR market. It will be interesting to see how the big guys respond to this because I have a feeling it could be a little problem for them, but should be good for Teviy. I havent checked the price of the stock but would expect little action. Any news coming out in this market is not being reflected in prices. You would think bad markets would make Teva boom. All those ulcers, headaches, and pains.... Ron